SCHEMBL18177404

SCHEMBL18177404

CNCc1ccc(C(=N)OC(=N)c2cncc(-c3ccc(S(=O)(=O)CCN(C)C)cc3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 6/20 0.41
▸ SYK P43405 6/20 0.34
▸ SCN10A Q9Y5Y9 4/20 0.33
▸ SCN2A Q99250 3/20 0.33
▸ JAK2 O60674 1/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ KIT P10721 1/20 0.32
▸ SERPINA2 P20848 1/20 0.32
▸ PIK3R1 P27986 1/20 0.32
▸ FLT4 P35916 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ MTOR P42345 1/20 0.32
▸ GSK3A P49840 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ PRKDC P78527 1/20 0.32
▸ MAP3K9 P80192 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ MERTK Q12866 1/20 0.32
▸ ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16489038 0.84 ATR (0.41) ATRSYKSCN10ASCN2AJAK2
SCHEMBL18180887 0.84 ATR (0.59) ATRSYKJAK2ABL1KIT
SCHEMBL18177406 0.81 SCN2A (0.38) ATRSCN10ASCN2APIK3CAMTOR
SCHEMBL18177400 0.80 ATR (0.53) ATRSYKSCN10ASCN2AJAK2
SCHEMBL18177386 0.80 ATR (0.41) ATRSYKSCN10ASCN2AJAK2
SCHEMBL18177413 0.79 ATR (0.41) ATRSYKSCN10ASCN2AJAK2
SCHEMBL18177408 0.79 NAMPT (0.42) —
SCHEMBL16489035 0.76 ATR (0.34) ATRSCN10ASCN2A
SCHEMBL17826209 0.75 ATR (0.41) ATRSYKJAK2ABL1KIT
SCHEMBL18177391 0.75 ATR (0.48) ATRSYKSCN10ASCN2AJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160311809-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311809-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885SYK 574/4885SCN10A 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback